Biogen shares tank on scrapping Alzheimer trials

Biogen and its partner, Eisai, are scrapping two late-stage trials for a potential treatment for Alzheimer's. As Fred Katayama reports, Biogen shares dropped 27 percent.

from Reuters Video: Business https://ift.tt/2HL7RPz